Granted Patent
B2
US 12,624,079 · App. 17/310,247 · Granted May 12, 2026
Process for preparing a GIP/GLP1 dual agonist
Inventors:
Michael Oliver Frederick (Zionsville, IN); Michael Eugene Kopach (Greenwood, IN); Sergey Vladimirovich Tsukanov (Indianapolis, IN)
Assignee:
ELI LILLY AND COMPANY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
Claims (2)
1 . A compound of SEQ ID NO:17, or a pharmaceutically acceptable salt thereof.
2 . A compound of SEQ ID NO:17, or a pharmaceutically acceptable salt thereof, wherein one or more selected from the group consisting of Fmoc, Boc, t-But, and trt protecting groups may be independently replaced by an alternative protecting group.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 27, 2021
From: COFFIN, STEPHANIE RUTH; FREDERICK, MICHAEL OLIVER; JALAN, ANKUR; KALLMAN, NEIL JOHN; KOPACH, MICHAEL EUGENE; SEIBERT, KEVIN DALE; TSUKANOV, SERGRY VLADIMIROVICH
To: ELI LILLY AND COMPANY
Reel/Frame 056992/0134 →
Continuity (4)
Provisional Application
62818342
· Mar 14, 2019
Provisional Application
62815053
· Mar 7, 2019
Provisional Application
62797963
· Jan 29, 2019
References Cited (35)
US 8129343B2
· Lau et al.
· 2012
[cited by applicant]
US 20110313131A1
· Carl et al.
· 2011
[cited by applicant]
CN 104356224A
· 2015
[cited by applicant]
CN 108676087A
· 2020
[cited by applicant]
WO 2007147816A1
· 2007
[cited by applicant]
WO 2009115469A1
· 2009
[cited by applicant]
WO 2010029159A1
· 2010
[cited by applicant]
WO 2010125079
· 2010
[cited by applicant]
WO 2011006644A2
· 2011
[cited by applicant]
WO 2011095989A2
· 2011
[cited by applicant]
WO 2015052088A1
· 2015
[cited by applicant]
WO 2016046753A1
· 2016
[cited by applicant]
WO 2016067271A1
· 2016
[cited by applicant]
WO 2016111971
· 2016
[cited by applicant]
WO 2021034815A1
· 2021
[cited by applicant]
International Search Report of the International Searching Authority pertaining to International Application No. PCT/US2020/015353; Date of Mailing: Jun. 24, 2020; 10 pages.
[cited by applicant]
Written Opinion of the International Search Report of the International Searching Authority pertaining to International Application No. PCT/US2020/015353; Date of Mailing: Jun. 24, 2020; 11 pages.
[cited by applicant]
Nyfeler, R. (1994). Peptide synthesis via fragment condensation.
[cited by applicant]
Mroz, Piotr A., et al. “Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.” Molecular Metabolism 20 (2019): 51-62.
[cited by applicant]
Zompra et al, “Manufacturing Peptides as Active Pharmaceutical Ingredients”, Future Medicinal Chemistry: Future Science, May 1, 2009, pp. 361-377, vol. 1, No. 2.
[cited by applicant]
Goodwin et al, “Peptides as Therapeutics with Enhanced Bioactivity”, Current Medicinal Chemistry, Dec. 31, 2012, pp. 4451-4461, vol. 19, No. 26.
[cited by applicant]
Frederick et al, “Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing”, American Chemical Society: Organic Process Research and Development, Jun. 17, 2021, pp. 1…
[cited by applicant]
European Search Report of EP20707971 (filed Jan. 28, 2020 by Eli Lilly and Company), Search completed on Feb. 24, 2025, Mailed on Mar. 4, 2025 by the European Patent Office, 19 pages.
[cited by applicant]
Richard Raz, et al. “HF-Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization”, Angewandte Chemie, Wiley-VCH, 2016, vol. 128 Issue: 42 pp. 13368-13373.
[cited by applicant]
Yahson Fernando and Varela Quitian, “Obtaining a High Molecular Weight Chimeric Peptide Derived From Plasmodium falciparum Proteins”, National University of Colombia, Department of Chemistry, 2016.
[cited by applicant]
Dou, et al., “Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris”, Protein Expression and Purification, vol…
[cited by applicant]
Frias, at at., “Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial”, The Lanc…
[cited by applicant]
Kulkarni, et al., “Rapid and efficient protein synthesis through expansion of the native chemical ligation concept”, Nature Reviews Chemistry, vol. 2, Article 0122, 2018, pp. 17.
[cited by applicant]
Malins, et al., “Synthetic Amino Acids for Applications in Peptide Ligation-Desulfurization Chemistry”, Aust. J. Chem., 2015, 68, 521-537.
[cited by applicant]
Paik, et al., “Comparability studies of new 3rd generation recombinant human factor VIII GreenGene F after improvement of formulation and viral inactivation/removal process”, Biologicals, vol. 40, Issue 6, 2012, pp. 405…
[cited by applicant]
Thapa, et al., “Native chemical ligation: a boon to peptide chemistry”, Molecules, 2014, 19, 14461-14483.
[cited by applicant]
Wan et al., “Free-Radical-Based, Specific Desulfurization of Cysteine: a Powerful Advance in the Synthesis of Polypeptides and Glycopolypeptides”, vol. 6, Issue 48, Angew. Chem. Int. Ed., Dec. 5, 2007, pp. 9248-9252.
[cited by applicant]
EP Patent Application No. 25200006.2, filed on Sep. 3, 2025 by Eli Lilly and Company. Extended European Search Report, search completed on Mar. 12, 2026, mailed on Mar. 23, 2026. 10 pages.
[cited by applicant]
EP Patent Application No. 25200026.0, filed on Sep. 3, 2025 by Eli Lilly and Company. Extended European Search Report, search completed on Mar. 12, 2026, mailed on Mar. 23, 2026. 10 pages.
[cited by applicant]